This is a preview of subscription content, log in via an institution to check access.
Reference
Barros FMR, et al. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil. Cost Effectiveness and Resource Allocation : 8 Oct 2013. Available from: URL: http://dx.doi.org/10.1186/1478-7547-11-25
Rights and permissions
About this article
Cite this article
Peginterferon-α-2a better option for hepatitis C in Brazil. PharmacoEcon Outcomes News 690, 9 (2013). https://doi.org/10.1007/s40274-013-0834-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0834-3